AstraZeneca (AZNCF) Stock Price, News & Analysis

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Key Stats

• Today's Range: $124.40 to $126.75
• 50-Day Range: $124.70 to $163.97
• 52-Week Range: $118.16 to $175.00
• Volume: 2,088 shs
• Average Volume: 2,650 shs
• Market Capitalization: N/A
• P/E Ratio: 152.82
• Dividend Yield: 2.25%
• Price Target: N/A
• Consensus Rating: N/A

AstraZeneca Stock Analysis - MarketRank™

AstraZeneca scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for AstraZeneca.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of AstraZeneca is 152.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 125.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of AstraZeneca is 152.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 89.56.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.

Change versus previous month

Short interest in AstraZeneca has recently increased by 13.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

AstraZeneca is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

AstraZeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of AstraZeneca is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.

Change versus previous month

Short interest in AstraZeneca has recently increased by 13.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.38

News Sentiment

AstraZeneca has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for AstraZeneca this week, compared to 6 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AstraZeneca insiders have not sold or bought any company stock.

Percentage Held by Institutions

40.87% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AZNCF Stock Analysis - Frequently Asked Questions

How have AZNCF shares performed this year?

AstraZeneca's stock was trading at $134.45 at the beginning of the year. Since then, AZNCF stock has decreased by 7.3% and is now trading at $124.70.
View the best growth stocks for 2024 here.

Who are AstraZeneca's major shareholders?

AstraZeneca's top institutional shareholders include Boston Common Asset Management LLC and Eagle Bay Advisors LLC.

How do I buy shares of AstraZeneca?

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Ex-Dividend for 9/9 Dividend: 8/07/2024
• Dividend Payable: 9/09/2024
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:AZNCF
• CUSIP: N/A
• CIK: 901832
• Web: www.astrazeneca.com
• Phone: 442037495000
• Fax: N/A
• Employees: 83,500
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 152.82
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A